Stockscreener 앱 받기
0.00
100.00%
-13.98
시간 외 거래:
12.80
12.80
+
전일 마감가:
$13.98
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$N/A
수익:
$107.00K
순이익/손실:
$-14.17M
주가수익비율:
0.00
EPS:
-8.8233
순현금흐름:
$-18.04M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
+245.37%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$14.75
Finch Therapeutics Group Inc Stock (FNCH) Company Profile
Compare FNCH vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FNCH
Finch Therapeutics Group Inc
|
0.00 | 0 | 107.00K | -14.17M | -18.04M | -8.8233 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Finch Therapeutics Group Inc Stock (FNCH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-08-09 | 개시 | H.C. Wainwright | Buy |
| 2021-04-13 | 개시 | BofA Securities | Buy |
| 2021-04-13 | 개시 | Evercore ISI | Outperform |
| 2021-04-13 | 개시 | Jefferies | Buy |
Finch Therapeutics Group Inc 주식(FNCH)의 최신 뉴스
Clostridium Difficile Infections Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Novartis AG, Astellas Pharma, Eli Lilly, AstraZeneca - Barchart.com
Microbiome Therapeutics Market Size, Share | Forecast [2034] - Fortune Business Insights
FNCH Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Finch Therapeutics Group (NASDAQ:FNCH) Trading Up 0.6% – Should You Buy? - Defense World
Global Clostridium Difficile Infections Clinical Trial Surges - openPR.com
Arquitos Capital Q4 2025 Investor Letter - Seeking Alpha
Human Microbiome Drugs Market worth $2.13 billion by 2031 | MarketsandMarkets™ - The Malaysian Reserve
Zenas BioPharma (NASDAQ:ZBIO) Downgraded by Morgan Stanley to Equal Weight - Defense World
Flutter Entertainment (NYSE:FLUT) Price Target Raised to $313.00 at Citizens Jmp - Defense World
WeRide (NASDAQ:WRD) Now Covered by Analysts at CLSA - Defense World
Perdoceo Education (NASDAQ:PRDO) Given Outperform Rating at Barrington Research - Defense World
QuinStreet’s (QNST) Outperform Rating Reaffirmed at Barrington Research - Defense World
Big Rock Brewery (TSE:BR) Shares Cross Below 50 Day Moving Average – What’s Next? - Defense World
Ionis Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:IONS) - Defense World
Human Microbiome Drugs Market Size & Growth Forecast to 2031 - MarketsandMarkets
Finch Therapeutics Group (NASDAQ:FNCH) vs. ZIVO Bioscience (NASDAQ:ZIVO) Financial Contrast - Defense World
Human Microbiome Drugs Market worth $2.13 billion by 2031 - MarketsandMarkets
Finch Therapeutics Group (NASDAQ:FNCH) Trading Down 3.9% – Should You Sell? - Defense World
North America Human Microbiome Market Size & Growth Forecast to 2031 - MarketsandMarkets
What Makes Finch Therapeutics (FNCH) a Worthy Investment? - Insider Monkey
Global Clostridium Difficile Infections Pipeline Expands With - openPR.com
Aecon Group (TSX:ARE): Valuation Check After Finch West LRT Revenue Service Milestone - simplywall.st
Biotech Companies Hire New Legal Leadership - BioXconomy
PepGen Appoints Joseph Vittiglio, Esq., as Chief Business and Legal Officer - BioSpace
PepGen appoints Joseph Vittiglio as chief business and legal officer By Investing.com - Investing.com Australia
Pepgen Inc. Appoints Joseph Vittiglio as Chief Business and Legal Officer, Effective December 8, 2025 - marketscreener.com
Crohn’s Disease Outlook Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight - The Globe and Mail
Autism Spectrum Disorder Pipeline Outlook Report 2025: Promising Drugs and MOA Innovations Reshape Future Treatment Approaches | DelveInsight - The Globe and Mail
Finch Therapeutics Group, Inc.Common Stock (OTC:FNCH) Stock Quote - Markets Financial Content
Microbiome Therapeutics Market Size to Hit USD 3,405.99 Million by 2034 - Precedence Research
Collective Growth (OTCMKTS:CGROU) Stock Price Up 7.6% – Here’s What Happened - Defense World
Finch Therapeutics Group (NASDAQ:FNCH) Shares Down 3.5% – What’s Next? - Defense World
MVPs: Kirkland's Adam Alper And Michael De Vries - Law360
Future Outlook: Human Microbiome Therapeutics Market to Hit USD 7.89 Billion by 2034, Growing at 22.80% - openPR.com
Free cash flow per share of Finch Therapeutics Group, Inc. – OTC:FNCH - TradingView
Arquitos Capital Management Q3 2025 Investor Letter - Seeking Alpha
Finch Secures $20 Million to Rebuild Consumer Law from the Ground Up - GlobeNewswire Inc.
Finch Secures $20 Million to Rebuild Consumer Law from the Ground Up - Yahoo Finance
United States Human Microbiome Market Set to Surge as Global Industry Projects USD 7.09 Billion Valuation by 2031 - vocal.media
Clostridium Difficile Infections Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Novartis AG, Astellas Pharma, Eli Lilly & Company AstraZeneca - Barchart.com
Microbiome Therapeutics Market Development and Global Outlook - Precedence Research
Clostridium Difficile Infections Pipeline 2025: Latest FDA - openPR.com
Microbiome Therapeutics Market Analysis – Demand, Drivers & Competitive Landscape 2025-2035 - pie-news.com
IMRX Rises on Pancreatic Cancer Findings, PEPG Achieves DM1 Splicing Correction Milestone, CLPT Under Observation - Intellectia AI
Hyundai Hope on Wheels and Finch Hyundai donate $140,000 to Children's Health Foundation toward the paediatric oncology program - Yahoo Finance
Analyzing Finch Therapeutics Group (NASDAQ:FNCH) and Genocea Biosciences (NASDAQ:GNCA) - Defense World
VivoSim Labs (VIVS) Short Interest & Short Float | Updated Mar 2026 $VIVS - MarketBeat
Delaware Powerhouse: Richards Layton - Law360
Human Microbiome Global Forecast Report 2025 | Market Set - GlobeNewswire
Microbiome startup MRM Health nabs €55M Series B to run Phase 2b ulcerative colitis trial - Endpoints News
Clostridioides difficile Infection Market Forecasts by DelveInsight Signal Groundbreaking Growth at a CAGR of 13.5% in the 7MM during the Forecast Period (2025-2034) - The Malaysian Reserve
Finch Therapeutics Group Inc (FNCH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.48%
1.21%
자본화:
|
볼륨(24시간):